171 patents currently held
38 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Sep 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
31
Ending by 2030
Sep 2027
Next term end
123
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2032 · High confidence
Also notable
Ends Sep 2027 · High confidence
Also notable
Ends Jul 2030 · High confidence
Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug
US 8,987,441
Cited by 58 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
Pyrimidine Compound and Medical Use Thereof
US 7,378,423
The most cited patent in this portfolio, cited by 63 later US patents, top 25% of utility patents granted in 2008 in our data. Protection runs to 2027.
Synthesis of Carbamoylpyridone HIV Integrase Inhibitors and Intermediates
US 8,624,023
Cited by 41 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Formerly held, still cited
Notable
Ends Oct 2027 · High confidence
The most cited patent in this portfolio, cited by 77 later US patents, top 10% of utility patents granted in 2012 in our data. Protection runs to 2027.
now held by Viiv Healthcare Company
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 25 to 27, 2026 · next Dec 25
- 1 fee due Jan 21, 2027The maintenance fee for Humanized PCRV Antibody Having Anti-Pseudomonal Activity (US 9,085,611) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
- 2 fees due Feb 18 to 27, 2027 · next Feb 18
- 1 fee due Mar 15, 2027The maintenance fee for (3S,11aR)-6-[(PHENYLMETHYL)OXY]-3-Methyl-2,3,11,11a-TETRAHYDROOXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-5,7-Dione OF THE FORMULA P-9 AND/OR (3S,11aR)-6-[(PHENYLMETHYL)OXY]-8-Bromo-3-Methyl-2,3,11,11a-TETRAHYDROOXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-5,7-Dione OF THE FORMULAP-10 (US 9,133,216) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 2 fees due Apr 6 to 22, 2027 · next Apr 6
- 3 fees due May 7 to 14, 2027 · next May 7
- 4 fees due Jun 1 to 24, 2027 · next Jun 1
- 4 fees due Jul 14 to 30, 2027 · next Jul 14
- 4 fees due Aug 4 to 25, 2027 · next Aug 4
- 7 fees due Sep 1 to 29, 2027 · next Sep 1
- 2 fees due Oct 19 to 28, 2027 · next Oct 19
- 1 fee due Nov 5, 2027The maintenance fee for Heterocycle Derivatives Having Trka Inhibitory Activity (US 10,640,495) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
- 4 of the patents on this record were granted since Aug 18, 2026
- 5 terms have ended since Aug 18, 2026
What they patent
The 5 largest of its 123 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,378,423 | Pyrimidine Compound and Medical Use Thereof In force · High confidence | In force | High confidence | |
| US 8,071,633 | Pharmaceutical Composition for Treating Spinocerebellar Ataxia In force · High confidence | In force | High confidence | |
| US 8,232,401 | 4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor In force · Medium confidence | In force | Medium confidence | |
| US 8,993,763 | Sulfonamide Derivative Having PGD2 Receptor Antagonistic Activity In force · Medium confidence | In force | Medium confidence | |
| US 8,202,879 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity In force · High confidence | In force | High confidence | |
| US 8,765,965 | 1-(2,3-Dihydroxypropyl)-4-OXO-3-[(PHENYLMETHYL)OXY]-1,4-Dihydro-2-Pyridinecarboxylic Acid of the Formula P-6 And/Or Methyl 1-(2,3-Dihydroxypropyl)-4-OXO-3-[(PHENYLMETHYL)OXY]-1,4-Dihydro-2-Pyridinecarboxylate of the Formula P-7 In force · High confidence | In force | High confidence | |
| US 8,940,912 | 4-OXO-3-[(PHENYLMETHYL)OXY]-4H-PYRAN-2-Carboxylic Acid In force · High confidence | In force | High confidence | |
| US 8,981,129 | 2-(2-Hydroxy-2-Phenylethyl)-3-[(PHENYLMETHYL)OXY]-4H-PYRAN-4-ONE of the Formula P-3 And/Or 2-[(E)-2-Phenylethenyl]-3-[(PHENYLMETHYL)OXY]-4H-PYRAN-4-ONE of the Formula P-4 In force · High confidence | In force | High confidence | |
| US 9,012,650 | SUBSTITUTED (3S, 11aR)-N-[(2,4-Difluorophenyl)METHYL]-6-OXY-3-Methyl-5,7-Dioxo-2,3,5,7,11,11a-HEXAHYDRO[1,3]OXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-8-Carboxamides OF FORMULA (I) USEFUL AS HIV AGENTS In force · Medium confidence | In force | Medium confidence | |
| US 9,133,216 | (3S,11aR)-6-[(PHENYLMETHYL)OXY]-3-Methyl-2,3,11,11a-TETRAHYDROOXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-5,7-Dione OF THE FORMULA P-9 AND/OR (3S,11aR)-6-[(PHENYLMETHYL)OXY]-8-Bromo-3-Methyl-2,3,11,11a-TETRAHYDROOXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-5,7-Dione OF THE FORMULAP-10 In force · High confidence | In force | High confidence |
Also on record, not counted in the 171: 38 patents in force now held by others · 221 patents ended · 78 applications pending · 178 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.